A Multicenter, Open Label Study to Assess the Safety and Efficacy of rIsankizuMab for MaInTenance in Moderate to Severe pLaquE Type Psoriasis (LIMMITLESS) | Dartmouth-Hitchcock
Skip to main content
x
Dartmouth-Hitchcock logo
Summer Flowers In This Section
 
A Multicenter, Open Label Study to Assess the Safety and Efficacy of rIsankizuMab for MaInTenance in Moderate to Severe pLaquE Type Psoriasis (LIMMITLESS)
Principal Investigator (?)
Study Number
F17040
Summary
The purpose of this study is to investigate the long-term safety and efficacy of risankizumab in the treatment of moderate to severe chronic plaque psoriasis. 
Phase (?)
Phase III
Sponsor (?)
Contact

Christine Neely-Jones

Available at the following location(s)

Lebanon

View more details from ClinicalTrials.gov.

0